The complete research debate on ultra-dilute homeopathic preparations — supporting work and the placebo consensus — presented together, in one place.
Each centesimal (C) step dilutes the preparation a hundred-fold. On a logarithmic scale the curve falls straight; by about 12C the chance of a single original molecule remaining is vanishingly small.
Research reporting possible bioactivity of ultra-dilute preparations.
In 2010, researchers at IIT Bombay (Chikramane, Suresh, Bellare, Kane) reported detecting nanoparticles of the original metals — gold, copper, tin, zinc, silver and platinum — still present in commercial samples at 30C and 200C, using transmission electron microscopy, electron diffraction and mass spectrometry; concentrations plateaued from around 6C onward at picogram-per-millilitre levels [14]. The group proposed a "froth flotation" mechanism explaining why dilution stops reducing the particle content (2012) and later reported hormetic cellular activation by metal nanoparticles from these preparations (2017) [15]. Other Indian groups reported crystalline nanoparticles in 15C plant-derived remedies (IIT Delhi / CCRH) and digoxin-like activity in Digitalis 30C–200C (IIT Kharagpur) [16]. On clinical evidence, Mathie's meta-analyses (2014, 2017) found individually prescribed homeopathy 1.5–2 times more likely than placebo to benefit patients, with risk-of-bias caveats, and a 2023 overview rated the cumulative evidence "high" for individualised treatment [17]. India's Central Council of Research in Homoeopathy runs government-funded trials across 18 conditions [19].
The placebo consensus of major reviews.
Several large assessments have concluded differently. Shang's 2005 Lancet analysis of 110 trials, the Australian NHMRC's 2015 evidence assessment, the European Academies' Science Advisory Council (2017), and the UK Parliament's Science & Technology Committee (2010) all found that well-conducted trials show no effect of homeopathy beyond placebo, and England's NICE recommends against homeopathy for the conditions it has assessed [7][8][9]. Critics of these reviews argue some positive trials were excluded and effects dismissed too readily; the NHMRC itself later clarified it had not concluded homeopathy was "ineffective," only that evidence of effect was lacking [9].
Three kinds of statement — kept apart on purpose
1. Classical claim
What the old materia medica says: the symptom picture a remedy is said to answer. This is tradition and testimony, recorded in the provings and clinical writings of the nineteenth century. It is what the Traditional picture block on every remedy page contains — and it is not evidence that the remedy works.
2. Pharmacological fact
What is established about the source substance: its chemistry, its toxicology, and where they exist, trials of the substance itself at ordinary doses. This is real science — but it is about the substance, not about a homeopathic preparation of it. It is the The substance in real medicine block.
3. Clinical evidence
What controlled trials of homeopathic preparations themselves show, including the systematic reviews that find effects no greater than placebo. This is the hardest test, and it is applied to the system as a whole rather than to any single portrait.
Why the three are separated here: a portrait can be faithfully described as tradition while the evidence for the preparation stays unproven — and a substance's pharmacology can be perfectly real while telling you nothing whatever about the remedy made from it.
Where the debate stands
Replication: independent laboratories have not consistently reproduced the nanoparticle findings, and reviewers note that adequate replication is still awaited [18].
Detection is not efficacy: showing that particles remain in a dilution answers a chemistry question; it does not by itself prove clinical benefit.
Trial quality: positive meta-analytic effects concentrate in trials with higher risk of bias; negative reviews weight rigorous trials most heavily.
Active research: the nanoparticle/hormesis programme continues, and national research bodies keep funding trials [15][19].